Description

Tirzepatide Research Topics:

1. Glycemic Control:

   It effectively lowers blood glucose levels in patients with type 2 diabetes, improving overall glycemic control (PMID: 35133415).

2. Weight Loss:

   Tirzepatide promotes substantial weight loss by enhancing satiety and reducing food intake (PMID: 36050763).

3. Cardiovascular Benefits:

   It reduces the risk of major adverse cardiovascular events, providing significant cardiovascular protection (PMID: 34819089).

4. Improved Insulin Sensitivity:

   The combination of GLP-1 and GIP effects enhances insulin sensitivity, further aiding metabolic health (PMID: 33236115).

Related Research

The differences in weight loss percentages for GLP-1 (Semaglutide), GLP-1/GIP (Tirzepatide), and GLP-1/GIP/GCGR (Retatrutide) are as follows:

1. Semaglutide (GLP-1):

   In clinical trials, Semaglutide resulted in a weight loss of approximately 12% over a period of 68 weeks (PMID: 32910488).

2. Tirzepatide (GLP-1/GIP):

   Tirzepatide demonstrated a weight loss ranging from 15% to 21% in different studies over a period of 72 weeks (PMID: 32910487).

3. Retatrutide (GLP-1/GIP/GCGR):

   In a phase 2 trial, Retatrutide showed a placebo-subtracted weight loss ranging from 6.6% to 22.1% over 48 weeks (PMID: 37366315).

Peer-Reviewed Studies 

• Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021). New England Journal of Medicine.

Frías J. P. (2020). Expert review of endocrinology & metabolism, 15(6), 379–394.

• The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes therapy: research, treatment, and education of diabetes and related disorders, 12(1), 143–157.

Min, T., & Bain, S. C. (2021).  Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … & Vilsbøll, T. (2016). N Engl J Med, 375, 1834-1844.

Structure

Amino Acid Sequence: YE-Aib-GTFTSDYSI-Aib­LDKIAQ (C20 fatty acid) AFVQWLIAGGPSSGAPPPS
Note: Aib is a non-coded (non-proteinogenic) amino acid – H2H-C(CH3)-COOH 

Molecular Formula: C22sH34sN4s06s

Molecular Weight: 4813.527 g/mol

PubChem CID: 156588324
CAS Number: 2023788-19-2

Synonyms:P1206,LY3298176

Source: PubChem